What it's for (Indications)
- Nicorandil is indicated for the prevention and long-term treatment of chronic stable angina pectoris in adult patients.
- It is typically utilized in situations where beta-blockers or calcium channel blockers are contraindicated, not tolerated, or do not provide adequate symptomatic control.
- The primary therapeutic objective of nicorandil therapy is to reduce the frequency and severity of anginal attacks and to improve exercise tolerance, thereby significantly enhancing the patient's overall quality of life.
- Its established efficacy in improving myocardial perfusion and reducing cardiac workload makes it a valuable pharmacological option in the comprehensive management of this debilitating cardiovascular condition, by helping to restore the critical balance between myocardial oxygen supply and demand.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended oral starting dose for nicorandil is typically 5 mg administered twice daily. The dosage can be gradually titrated upwards, based on the individual patient's clinical response and tolerability, usually progressing to a maintenance dose of 10 mg or 20 mg twice daily. The maximum recommended daily dose is generally 20 mg twice daily, totaling 40 mg per day. Dosage adjustments may be necessary in patients with impaired renal function, although severe renal impairment requires particular caution and close monitoring. It is crucial to initiate treatment with a low dose and to increase it incrementally to minimize the risk of dose-dependent adverse effects, such as headache and flushing, which are commonly experienced upon therapy initiation. Administration should be consistent, preferably with meals, to ensure optimal absorption and minimize potential gastrointestinal upset. |
Safety & Warnings
Common Side Effects
- Common side effects associated with nicorandil treatment include headache, particularly during the initial phases of therapy, which is often dose-dependent and typically tends to diminish with continued use.
- Other frequently reported adverse reactions encompass dizziness, facial flushing, nausea, vomiting, and palpitations.
- More serious but less common side effects include the development of gastrointestinal, cutaneous, or ocular ulcerations.
- These ulcers can be severe, persistent, and recurrent, sometimes necessitating surgical intervention and potentially leading to complications like perforation, fistula formation, or hemorrhage.
- Other potential adverse effects include symptomatic hypotension, especially at higher doses or in susceptible individuals, and rarely, pancreatitis, myalgia, and various types of skin rash.
- Patients should be advised to promptly report any persistent or worsening symptoms to their healthcare provider for evaluation.
Serious Warnings
- Black Box Warning: Nicorandil is not approved by the U.S. Food and Drug Administration (FDA) and therefore does not carry an official FDA-mandated Black Box Warning. However, based on its established safety profile and clinical experience in countries where it is approved, **serious warnings** regarding the potential for severe mucocutaneous ulcerations are critically important and warrant explicit emphasis. These include documented reports of deep, persistent, and painful ulcers affecting various parts of the gastrointestinal tract (e.g., oral, anal, esophageal, gastric, colonic, small intestinal), skin, and eyes. These ulcers can lead to significant and severe complications such as hemorrhage, perforation, fistula formation, or abscesses, often requiring surgical intervention and prolonged hospitalization. Patients must be thoroughly counseled on the signs and symptoms of these debilitating ulcers and advised to seek immediate medical attention if they manifest. Furthermore, the absolute contraindication for concomitant use with phosphodiesterase-5 (PDE5) inhibitors or soluble guanylate cyclase stimulators due to the risk of profound and life-threatening hypotension constitutes a critical safety alert, demanding comprehensive communication to both prescribing healthcare professionals and patients.
- Nicorandil is associated with several serious warnings that necessitate careful consideration during prescription and patient management.
- Foremost among these is the significant risk of developing severe gastrointestinal, cutaneous, ocular, and other mucocutaneous ulcerations.
- These ulcers can manifest anywhere along the gastrointestinal tract, from the oral cavity to the anus, and may be deep, persistent, and highly painful.
- They can lead to severe complications such such as perforation, fistula formation, or life-threatening hemorrhage, often requiring surgical intervention and prolonged hospitalization.
- Patients must be educated to report any new or worsening ulcers, unexplained abdominal pain, or signs of gastrointestinal bleeding immediately.
- Concomitant use with phosphodiesterase-5 (PDE5) inhibitors (e.
- g.
- , sildenafil, tadalafil, vardenafil) is strictly contraindicated due to the potential for severe, profound, and life-threatening hypotension.
- Similarly, co-administration with soluble guanylate cyclase stimulators (e.
- g.
- , riociguat) is also absolutely contraindicated.
- Caution is strongly advised in patients with pre-existing heart failure or hypovolemia, as nicorandil's potent vasodilatory effects can exacerbate hypotension.
- Patients with glaucoma should be monitored, as increased intraocular pressure has been reported in rare instances.
How it Works (Mechanism of Action)
Nicorandil exerts its anti-anginal effects through a unique dual mechanism of action, making it distinct from traditional nitrates. Firstly, it functions as a potent potassium channel activator, specifically targeting and opening ATP-sensitive potassium (K_ATP) channels located in vascular smooth muscle cells. This activation leads to hyperpolarization of the cell membrane, which subsequently reduces calcium influx and results in profound vasodilation of both arterial and venous vessels. Arterial dilation effectively reduces systemic vascular resistance (afterload), while venous dilation decreases venous return to the heart (preload). Secondly, nicorandil possesses nitrate-like properties, acting as a nitric oxide (NO) donor. NO stimulates soluble guanylate cyclase, leading to an increase in intracellular cyclic guanosine monophosphate (cGMP) levels, which further promotes smooth muscle relaxation and vasodilation. This synergistic dual action ultimately leads to improved coronary blood flow, reduced myocardial oxygen demand, and enhanced oxygen supply, thereby effectively alleviating angina symptoms and improving myocardial oxygenation.